The Picostim system was originally developed as a cranial implant for delivering deep brain stimulation (DBS) to treat patients with Parkinson’s disease. The system was further enhanced by the development of the DyNeuMo firmware which enables fully adaptive therapy capability and formed the basis of the Picostim DyNeuMo research platform. Amber continues its support of the research platform by supplying devices for multiple first-in-human trials sponsored by a consortium of academic collaborators led by those at the University of Oxford.